Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Ping-Tee Tan, Mohamed Ismail Abdul Aziz, Fiona Pearce, Wan-Teck Lim, David Bin-Chia Wu, Kwong Ng

ABSTRACT

BACKGROUND: Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-line treatment for NSCLC which harbours an epidermal growth factor receptor (EGFR) mutation. The objective of this study was to evaluate the cost-effectiveness of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive NSCLC in Singapore. METHODS: A partitioned survival model with three health states (progression-free, progressive disease and death) was developed from a healthcare payer perspective. Survival curves from the LUX-Lung 3 trial (afatinib versus pemetrexed-cisplatin chemotherapy) were extrapolated beyond the trial period to estimate the underlying progression-free survival and overall survival parametric distributions. Rates of adverse reactions were also estimated from LUX-Lung 3 while health utilities from overseas were derived from the literature in the absence of local estimates. Direct costs were sourced from public healthcare institutions in Singapore. Incremental cost-effectiveness ratios (ICERs) were calculated over a 5 year time horizon. Deterministic and probabilistic sensitivity analyses and additional scenario analyses were conducted to explore the impact of uncertainties and assumptions on the cost-effectiveness results. RESULTS: In the base-case analysis, the ICER for afatinib versus pemetrexed-cisplatin was SG$137,648 per quality-adjusted life year (QALY) gained and SG$109,172 per life-year gained. One-way sensitivity analysis showed the ICER was most sensitive to variations in the utility values, the cost of afatinib and time horizon. Scenario analyses showed that even reducing the cost of afatinib by 50% led to a high ICER which was unlikely to represent a cost-effective use of healthcare resources. CONCLUSIONS: Compared with pemetrexed-cisplatin, afatinib is not cost-effective as a first-line treatment for advanced EGFR mutation-positive NSCLC in Singapore. The findings from our study will be useful to inform local healthcare decision-making and resource allocations for NSCLC treatments, together with other considerations such as clinical effectiveness, safety and affordability of TKIs. More... »

PAGES

352

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y

DOI

http://dx.doi.org/10.1186/s12885-018-4223-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101785426

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29587666


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Afatinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Care Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pemetrexed", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Singapore", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tan", 
        "givenName": "Ping-Tee", 
        "id": "sg:person.013437617370.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013437617370.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aziz", 
        "givenName": "Mohamed Ismail Abdul", 
        "id": "sg:person.014456032113.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014456032113.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pearce", 
        "givenName": "Fiona", 
        "id": "sg:person.015630140770.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015630140770.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Centre Singapore", 
          "id": "https://www.grid.ac/institutes/grid.410724.4", 
          "name": [
            "Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, 169610, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lim", 
        "givenName": "Wan-Teck", 
        "id": "sg:person.0736043070.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736043070.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wu", 
        "givenName": "David Bin-Chia", 
        "id": "sg:person.014462711604.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014462711604.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ng", 
        "givenName": "Kwong", 
        "id": "sg:person.011536243313.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011536243313.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/mdu199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001793280"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv270", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001810535"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.36.8456", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002674515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e318299243b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004009500"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70393-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004429924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.26372", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013460032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.26372", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013460032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00121-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014173002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds214", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019179559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70184-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019948065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.2806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022055849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.2806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022055849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.4235", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022283608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.4235", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022283608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2015.04.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028072476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu123", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033797914"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71173-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036794393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70375-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036824416"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.1711", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036846263"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2288-11-139", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037378478", 
          "https://doi.org/10.1186/1471-2288-11-139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv276", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043154035"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-6-84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044187224", 
          "https://doi.org/10.1186/1477-7525-6-84"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(09)70364-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046378249"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30033-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047011654"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2011.05.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047222743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0000000000000033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049707999"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.41.2056", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051506609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.02.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051872458"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053632002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-6687(03)00118-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054621115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-6687(03)00118-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054621115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta14suppl2/10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079210843", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.32.15_suppl.8117", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111107399"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-line treatment for NSCLC which harbours an epidermal growth factor receptor (EGFR) mutation. The objective of this study was to evaluate the cost-effectiveness of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive NSCLC in Singapore.\nMETHODS: A partitioned survival model with three health states (progression-free, progressive disease and death) was developed from a healthcare payer perspective. Survival curves from the LUX-Lung 3 trial (afatinib versus pemetrexed-cisplatin chemotherapy) were extrapolated beyond the trial period to estimate the underlying progression-free survival and overall survival parametric distributions. Rates of adverse reactions were also estimated from LUX-Lung 3 while health utilities from overseas were derived from the literature in the absence of local estimates. Direct costs were sourced from public healthcare institutions in Singapore. Incremental cost-effectiveness ratios (ICERs) were calculated over a 5\u00a0year time horizon. Deterministic and probabilistic sensitivity analyses and additional scenario analyses were conducted to explore the impact of uncertainties and assumptions on the cost-effectiveness results.\nRESULTS: In the base-case analysis, the ICER for afatinib versus pemetrexed-cisplatin was SG$137,648 per quality-adjusted life year (QALY) gained and SG$109,172 per life-year gained. One-way sensitivity analysis showed the ICER was most sensitive to variations in the utility values, the cost of afatinib and time horizon. Scenario analyses showed that even reducing the cost of afatinib by 50% led to a high ICER which was unlikely to represent a cost-effective use of healthcare resources.\nCONCLUSIONS: Compared with pemetrexed-cisplatin, afatinib is not cost-effective as a first-line treatment for advanced EGFR mutation-positive NSCLC in Singapore. The findings from our study will be useful to inform local healthcare decision-making and resource allocations for NSCLC treatments, together with other considerations such as clinical effectiveness, safety and affordability of TKIs.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-018-4223-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "name": "Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer\u2019s perspective", 
    "pagination": "352", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7ca9e810fb4d50d6d77e4f907a7002bf13aafb90e2377f5eccb4201b3f08b9ab"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29587666"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-018-4223-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101785426"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-018-4223-y", 
      "https://app.dimensions.ai/details/publication/pub.1101785426"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000367_0000000367/records_88247_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-018-4223-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y'


 

This table displays all metadata directly associated to this object as RDF triples.

261 TRIPLES      21 PREDICATES      75 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-018-4223-y schema:about N086e89670ea440419c44d66dbe63718e
2 N1562ebf9da164a8f9d781b5b12df9c89
3 N259da43eb72a4ae08b777dda765e3f9a
4 N25c7970a2d04464688186df57c7d6de4
5 N3353ffff18824574aae8aef08b14a9a5
6 N47c9a1c04ae8408a94cf8e777ba16b51
7 N582be161cb5d4b8ab36b9b49b5a2bbd5
8 N5b4e1ba82fa54c09af1bfb7106f317a4
9 N5bdd0ec6d36a45be87acb98e625b301a
10 N7fb7b70a524247f4bdd78ebf68478feb
11 Na3b88c50c5444d94870d42f17a7d60c3
12 Nacb4c208a93d43898ae71decbcc5fb98
13 Nb072db9acc6d4f37a92424396985e3bc
14 Nd3bd2e0f612243dd89f389cbf9a8cfa2
15 Ne405e99c104045e5a9f5507fde3bb17c
16 Nf1d40fc66b7e4ed2bd7ef563faebe448
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author Ndf3deb89f1644cf5a411e70e2d0001d0
20 schema:citation sg:pub.10.1186/1471-2288-11-139
21 sg:pub.10.1186/1477-7525-6-84
22 https://app.dimensions.ai/details/publication/pub.1079210843
23 https://doi.org/10.1002/cncr.26372
24 https://doi.org/10.1016/j.ejca.2011.02.013
25 https://doi.org/10.1016/j.jval.2015.04.008
26 https://doi.org/10.1016/j.lungcan.2011.05.022
27 https://doi.org/10.1016/s0167-6687(03)00118-5
28 https://doi.org/10.1016/s1470-2045(09)70364-x
29 https://doi.org/10.1016/s1470-2045(11)70184-x
30 https://doi.org/10.1016/s1470-2045(11)70393-x
31 https://doi.org/10.1016/s1470-2045(14)70375-4
32 https://doi.org/10.1016/s1470-2045(14)71173-8
33 https://doi.org/10.1016/s1470-2045(15)00121-7
34 https://doi.org/10.1016/s1470-2045(16)30033-x
35 https://doi.org/10.1093/annonc/mds214
36 https://doi.org/10.1093/annonc/mdu123
37 https://doi.org/10.1093/annonc/mdu199
38 https://doi.org/10.1093/annonc/mdv270
39 https://doi.org/10.1093/annonc/mdv276
40 https://doi.org/10.1097/jto.0000000000000033
41 https://doi.org/10.1097/jto.0b013e318299243b
42 https://doi.org/10.1158/1078-0432.ccr-12-2934
43 https://doi.org/10.1200/jco.2008.16.1711
44 https://doi.org/10.1200/jco.2010.33.4235
45 https://doi.org/10.1200/jco.2011.36.8456
46 https://doi.org/10.1200/jco.2011.41.2056
47 https://doi.org/10.1200/jco.2012.44.2806
48 https://doi.org/10.1200/jco.2014.32.15_suppl.8117
49 https://doi.org/10.3310/hta14suppl2/10
50 schema:datePublished 2018-12
51 schema:datePublishedReg 2018-12-01
52 schema:description BACKGROUND: Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-line treatment for NSCLC which harbours an epidermal growth factor receptor (EGFR) mutation. The objective of this study was to evaluate the cost-effectiveness of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive NSCLC in Singapore. METHODS: A partitioned survival model with three health states (progression-free, progressive disease and death) was developed from a healthcare payer perspective. Survival curves from the LUX-Lung 3 trial (afatinib versus pemetrexed-cisplatin chemotherapy) were extrapolated beyond the trial period to estimate the underlying progression-free survival and overall survival parametric distributions. Rates of adverse reactions were also estimated from LUX-Lung 3 while health utilities from overseas were derived from the literature in the absence of local estimates. Direct costs were sourced from public healthcare institutions in Singapore. Incremental cost-effectiveness ratios (ICERs) were calculated over a 5 year time horizon. Deterministic and probabilistic sensitivity analyses and additional scenario analyses were conducted to explore the impact of uncertainties and assumptions on the cost-effectiveness results. RESULTS: In the base-case analysis, the ICER for afatinib versus pemetrexed-cisplatin was SG$137,648 per quality-adjusted life year (QALY) gained and SG$109,172 per life-year gained. One-way sensitivity analysis showed the ICER was most sensitive to variations in the utility values, the cost of afatinib and time horizon. Scenario analyses showed that even reducing the cost of afatinib by 50% led to a high ICER which was unlikely to represent a cost-effective use of healthcare resources. CONCLUSIONS: Compared with pemetrexed-cisplatin, afatinib is not cost-effective as a first-line treatment for advanced EGFR mutation-positive NSCLC in Singapore. The findings from our study will be useful to inform local healthcare decision-making and resource allocations for NSCLC treatments, together with other considerations such as clinical effectiveness, safety and affordability of TKIs.
53 schema:genre research_article
54 schema:inLanguage en
55 schema:isAccessibleForFree true
56 schema:isPartOf N3d2a0eb6fcf84c81a40b1c5f233c2b30
57 Nbbdf480fac444336b9963d1c1daf9b00
58 sg:journal.1024632
59 schema:name Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
60 schema:pagination 352
61 schema:productId N1485a716553e4cbeaed22ef67e4e1d70
62 N5348d1d1802a40d79fc8a14b616a9812
63 N813a4cca23b040e9846910e718324408
64 N8e707736b2144c46b4e96ebf1b6e4e47
65 N975793c6ab0345aa99663007edb6038b
66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101785426
67 https://doi.org/10.1186/s12885-018-4223-y
68 schema:sdDatePublished 2019-04-11T13:10
69 schema:sdLicense https://scigraph.springernature.com/explorer/license/
70 schema:sdPublisher N828ea8eef27847068de6790ec8787977
71 schema:url https://link.springer.com/10.1186%2Fs12885-018-4223-y
72 sgo:license sg:explorer/license/
73 sgo:sdDataset articles
74 rdf:type schema:ScholarlyArticle
75 N086e89670ea440419c44d66dbe63718e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Health Care Costs
77 rdf:type schema:DefinedTerm
78 N1485a716553e4cbeaed22ef67e4e1d70 schema:name doi
79 schema:value 10.1186/s12885-018-4223-y
80 rdf:type schema:PropertyValue
81 N1562ebf9da164a8f9d781b5b12df9c89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Singapore
83 rdf:type schema:DefinedTerm
84 N259da43eb72a4ae08b777dda765e3f9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Neoplasm Metastasis
86 rdf:type schema:DefinedTerm
87 N25c7970a2d04464688186df57c7d6de4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Treatment Outcome
89 rdf:type schema:DefinedTerm
90 N3353ffff18824574aae8aef08b14a9a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Afatinib
92 rdf:type schema:DefinedTerm
93 N3d2a0eb6fcf84c81a40b1c5f233c2b30 schema:issueNumber 1
94 rdf:type schema:PublicationIssue
95 N47c9a1c04ae8408a94cf8e777ba16b51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Humans
97 rdf:type schema:DefinedTerm
98 N5348d1d1802a40d79fc8a14b616a9812 schema:name pubmed_id
99 schema:value 29587666
100 rdf:type schema:PropertyValue
101 N582be161cb5d4b8ab36b9b49b5a2bbd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Prognosis
103 rdf:type schema:DefinedTerm
104 N5b4e1ba82fa54c09af1bfb7106f317a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Neoplasm Staging
106 rdf:type schema:DefinedTerm
107 N5bdd0ec6d36a45be87acb98e625b301a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Cisplatin
109 rdf:type schema:DefinedTerm
110 N6f646aed62974395a55a47c6b8923784 rdf:first sg:person.011536243313.55
111 rdf:rest rdf:nil
112 N7421086e00d04e3a89100a22e5767ccd rdf:first sg:person.015630140770.11
113 rdf:rest N94c53fc340c845aeb8951263af61883f
114 N7fb7b70a524247f4bdd78ebf68478feb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Mutation
116 rdf:type schema:DefinedTerm
117 N813a4cca23b040e9846910e718324408 schema:name dimensions_id
118 schema:value pub.1101785426
119 rdf:type schema:PropertyValue
120 N828ea8eef27847068de6790ec8787977 schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 N82ce3f48181e40c7bdd5125589dcebf3 rdf:first sg:person.014456032113.19
123 rdf:rest N7421086e00d04e3a89100a22e5767ccd
124 N8e707736b2144c46b4e96ebf1b6e4e47 schema:name readcube_id
125 schema:value 7ca9e810fb4d50d6d77e4f907a7002bf13aafb90e2377f5eccb4201b3f08b9ab
126 rdf:type schema:PropertyValue
127 N94c53fc340c845aeb8951263af61883f rdf:first sg:person.0736043070.06
128 rdf:rest Nb0728d0bab024556bed72eb9c510791f
129 N975793c6ab0345aa99663007edb6038b schema:name nlm_unique_id
130 schema:value 100967800
131 rdf:type schema:PropertyValue
132 Na3b88c50c5444d94870d42f17a7d60c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Lung Neoplasms
134 rdf:type schema:DefinedTerm
135 Nacb4c208a93d43898ae71decbcc5fb98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Pemetrexed
137 rdf:type schema:DefinedTerm
138 Nb0728d0bab024556bed72eb9c510791f rdf:first sg:person.014462711604.46
139 rdf:rest N6f646aed62974395a55a47c6b8923784
140 Nb072db9acc6d4f37a92424396985e3bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Carcinoma, Non-Small-Cell Lung
142 rdf:type schema:DefinedTerm
143 Nbbdf480fac444336b9963d1c1daf9b00 schema:volumeNumber 18
144 rdf:type schema:PublicationVolume
145 Nd3bd2e0f612243dd89f389cbf9a8cfa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name ErbB Receptors
147 rdf:type schema:DefinedTerm
148 Ndf3deb89f1644cf5a411e70e2d0001d0 rdf:first sg:person.013437617370.71
149 rdf:rest N82ce3f48181e40c7bdd5125589dcebf3
150 Ne405e99c104045e5a9f5507fde3bb17c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Antineoplastic Combined Chemotherapy Protocols
152 rdf:type schema:DefinedTerm
153 Nf1d40fc66b7e4ed2bd7ef563faebe448 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Cost-Benefit Analysis
155 rdf:type schema:DefinedTerm
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
160 schema:name Oncology and Carcinogenesis
161 rdf:type schema:DefinedTerm
162 sg:journal.1024632 schema:issn 1471-2407
163 schema:name BMC Cancer
164 rdf:type schema:Periodical
165 sg:person.011536243313.55 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
166 schema:familyName Ng
167 schema:givenName Kwong
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011536243313.55
169 rdf:type schema:Person
170 sg:person.013437617370.71 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
171 schema:familyName Tan
172 schema:givenName Ping-Tee
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013437617370.71
174 rdf:type schema:Person
175 sg:person.014456032113.19 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
176 schema:familyName Aziz
177 schema:givenName Mohamed Ismail Abdul
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014456032113.19
179 rdf:type schema:Person
180 sg:person.014462711604.46 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
181 schema:familyName Wu
182 schema:givenName David Bin-Chia
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014462711604.46
184 rdf:type schema:Person
185 sg:person.015630140770.11 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
186 schema:familyName Pearce
187 schema:givenName Fiona
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015630140770.11
189 rdf:type schema:Person
190 sg:person.0736043070.06 schema:affiliation https://www.grid.ac/institutes/grid.410724.4
191 schema:familyName Lim
192 schema:givenName Wan-Teck
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736043070.06
194 rdf:type schema:Person
195 sg:pub.10.1186/1471-2288-11-139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037378478
196 https://doi.org/10.1186/1471-2288-11-139
197 rdf:type schema:CreativeWork
198 sg:pub.10.1186/1477-7525-6-84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044187224
199 https://doi.org/10.1186/1477-7525-6-84
200 rdf:type schema:CreativeWork
201 https://app.dimensions.ai/details/publication/pub.1079210843 schema:CreativeWork
202 https://doi.org/10.1002/cncr.26372 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013460032
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/j.ejca.2011.02.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051872458
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/j.jval.2015.04.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028072476
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/j.lungcan.2011.05.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047222743
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1016/s0167-6687(03)00118-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054621115
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1016/s1470-2045(09)70364-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046378249
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1016/s1470-2045(11)70184-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019948065
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/s1470-2045(11)70393-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004429924
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/s1470-2045(14)70375-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036824416
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/s1470-2045(14)71173-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036794393
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s1470-2045(15)00121-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014173002
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/s1470-2045(16)30033-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047011654
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1093/annonc/mds214 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019179559
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1093/annonc/mdu123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033797914
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1093/annonc/mdu199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001793280
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1093/annonc/mdv270 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001810535
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1093/annonc/mdv276 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043154035
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1097/jto.0000000000000033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049707999
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1097/jto.0b013e318299243b schema:sameAs https://app.dimensions.ai/details/publication/pub.1004009500
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1158/1078-0432.ccr-12-2934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053632002
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2008.16.1711 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036846263
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2010.33.4235 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022283608
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2011.36.8456 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002674515
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2011.41.2056 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051506609
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2012.44.2806 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022055849
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1200/jco.2014.32.15_suppl.8117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111107399
253 rdf:type schema:CreativeWork
254 https://doi.org/10.3310/hta14suppl2/10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139213
255 rdf:type schema:CreativeWork
256 https://www.grid.ac/institutes/grid.410724.4 schema:alternateName National Cancer Centre Singapore
257 schema:name Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, 169610, Singapore, Singapore
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.415698.7 schema:alternateName Ministry of Health
260 schema:name Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore
261 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...